Cytokinetics (CYTK) and Its Competitors Financial Contrast
Cytokinetics (NASDAQ: CYTK) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Cytokinetics to similar companies based on the strength of its institutional ownership, valuation, profitability, risk, dividends, analyst recommendations and earnings.
Insider and Institutional Ownership
73.7% of Cytokinetics shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 7.2% of Cytokinetics shares are owned by insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares Cytokinetics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and recommmendations for Cytokinetics and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cytokinetics currently has a consensus price target of $17.90, indicating a potential upside of 132.47%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 44.60%. Given Cytokinetics’ stronger consensus rating and higher probable upside, analysts clearly believe Cytokinetics is more favorable than its peers.
Volatility & Risk
Cytokinetics has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Comparatively, Cytokinetics’ peers have a beta of 5.97, indicating that their average share price is 497% more volatile than the S&P 500.
Valuation and Earnings
This table compares Cytokinetics and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cytokinetics||$106.41 million||$16.45 million||-4.64|
|Cytokinetics Competitors||$284.28 million||$33.78 million||83.25|
Cytokinetics’ peers have higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Cytokinetics beats its peers on 7 of the 12 factors compared.
Cytokinetics Company Profile
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.